CDNA · CareDx, Inc. · Stock research

= # CDNA — CareDx, Inc.

Current Thesis

The leg on offer is unchanged in kind and further along in time: a reimbursement-validated surveillance-testing franchise whose estimates are still being revised upward. The 2026-07-16 final MolDX Local Coverage Determination removed the coverage overhang that had capped this equity since 2023, and the 2026-07-30 Q2 report converted it into P&L — revenue $131.948M against a $114.044M consensus, adjusted EPS $0.37 against $0.23, testing services $100M (+61% YoY), adjusted EBITDA $25M versus $5M a year earlier — with FY2026 revenue guidance raised to $490–500M from $447–465M. What has changed since early August is not the fundamentals but the flow around them. The last dated company headline was the 2026-08-07 inducement-grant announcement; the last analyst action was BTIG's $60 target on 2026-08-06; and the stock ground to a new closing high of $48.61 on 2026-08-21 with RSI(14) at 53.3, down from 70.1 on 2026-08-07. Momentum cooled while price held — inferred from those two readings, the tape spent a fortnight digesting the July repricing rather than extending it. The 2026-08-30 LCD effective date is now the near event, and management has already sized its 2026 contribution at roughly $7.5M, which puts the reimbursement economics in 2027 and makes the coming week a policy-mechanics check rather than a revenue check.

Bullish and bearish views on CareDx, Inc.

The model's bull view on CareDx, Inc. (CDNA), in brief: Guidance was raised twice inside fifteen days. The bear view: Two further notices followed — 7,000 shares valued $328,237.70 (planned 2026-08-12) and 9,122 shares valued $423,091.13 (filed 2026-08-17). Both cases follow in full.

Bull Case

• Guidance was raised twice inside fifteen days. FY2026 revenue went $420–444M → $447–465M (2026-07-16, with the LCD) → $490–500M (2026-07-30) against a $455.924M consensus; FY adjusted EBITDA moved to $66–78M from $43–57M.
• Q2 2026 (2026-07-30) beat both lines — revenue $131.948M vs $114.044M consensus, adjusted EPS $0.37 vs $0.23 — on ~58,000 tests, +17% YoY, with non-GAAP gross margin 74%.
• The volume framework is disclosed and checkable. FY2026 guided to 258,000–266,000 tests, so each quarterly print grades the guide rather than the story.
• Named-analyst work has moved far above the aggregate. Craig-Hallum upgraded to Buy on 2026-08-03 and lifted its target to $64 from $35, citing expanded coverage, added indications and Naveris; BTIG maintained Buy and raised to $60 on 2026-08-06 after $45 on 2026-07-16 and $28 before that. Aggregated consensus screens sampled 2026-08-22 still showed a mean in the mid-$20s from seven analysts, so the published aggregate has not absorbed either action.
• Balance sheet repaired and redeployed. Cash and equivalents $373.6M at 2026-06-30 after the $171.2M Lab Products sale to Eurobio Scientific (closed 2026-06-30); Naveris closed 2026-07-01 for $160M upfront plus up to $100M in revenue milestones, adding NavDx, a TTMV-DNA assay with Medicare coverage since 2023.
• The 2026-08-21 high was made without a fresh catalyst. No dated company news between 2026-08-07 and 2026-08-21, yet the closing high was taken — an absence of supply at the top of the July range, measured only by those closes.

Bear Case

• Two further notices followed — 7,000 shares valued $328,237.70 (planned 2026-08-12) and 9,122 shares valued $423,091.13 (filed 2026-08-17).
• Price sits above most published targets. HC Wainwright reiterated Neutral with a $46 target on 2026-07-31, below the 2026-08-21 close of $48.61. Only BTIG's $60 and Craig-Hallum's $64 sit above the market.
• The 2026-08-30 event pays almost nothing this year. Management's own ~$7.5M sizing of the 2026 LCD benefit means the effective date resolves policy risk, not numbers, and the accompanying billing or frequency guidance from the contractor is the same mechanism that broke this equity in 2023.
• Growth composition is price- and mix-led. Testing-services revenue +61% YoY against +17% volume growth in Q2; the gap is rate and mix, and rate resets do not repeat annually.
• The GAAP quarter is flattered. Q2 GAAP net income of $111M includes a $113M gain on the Lab Products divestiture, excluded from non-GAAP. Underlying quarterly earnings power is the $25M adjusted EBITDA figure.
• Comparability breaks in the current quarter. Lab Products left on 2026-06-30 and Naveris arrived on 2026-07-01, so the September quarter is the first period with neither a clean prior-year comparison nor, so far, a separately disclosed NavDx line.

Setup & Price Structure

The narrative is maturing. The narrative is fully public — the 2026-07-16 session moved the stock ~28% and the name appeared in three separate Benzinga "stocks moving" roundups on 2026-07-16, 2026-07-30 and 2026-07-31 — and it is still working, with a new closing high on 2026-08-21. What dates the label is the moderation: the target-raise stream stopped on 2026-08-06, no company headline printed between 2026-08-07 and 2026-08-21, and RSI(14) fell from 70.1 to 53.3 across that stretch while the closing price moved only from $46.69 to $48.61. That is a narrative absorbing its own repricing, not one drawing fresh participants. It is not saturated: seven analysts cover it, and the consensus aggregate is still roughly half the market price.

Observables on positioning, without a verdict attached to them: the shares are 124.7% higher over three months and the 2026-08-21 close of $48.61 is the 52-week high, so the entire cohort from the July gap-up onward is above water and nothing above is trapped; the three observed August closes ($46.69 on 2026-08-07, $47.23 on 2026-08-11, $48.61 on 2026-08-21) describe a narrow shelf rather than a trend leg; a director sold into every one of those weeks; and the company issued 97,090 inducement RSUs to 35 new employees announced 2026-08-07 — hiring dilution, not a capital raise. The next earnings date is roughly ten weeks out, so there is no print inside the window to compress the range.

Catalyst Calendar (next 30 days)

• 2026-08-30 — MolDX Local Coverage Determination for molecular testing in solid organ allograft rejection takes formal effect. Surveillance dd-cfDNA coverage for kidney, heart and lung transplant recipients begins; it is also the natural moment for the contractor to publish accompanying billing/coding or frequency guidance.
• ~2026-09-30 (est.) — quarter-end: the first full period carrying Naveris/NavDx and the first without Lab Products, and therefore the first clean read on post-deal mix against the $490–500M FY guide.
• ~2026-10-29 (est.) — Q3 2026 earnings, date unconfirmed and outside the 30-day window. First hard test of the raised revenue guide and the 258,000–266,000 volume range, and the first quarter in which rate and volume effects can be separated.

What Would Change Our Mind

The structure that matters is the August shelf built between the 2026-08-07 and 2026-08-21 closes, which sits on top of the 2026-07-30 post-print repricing. Losing that shelf entirely — a weekly close below $42 — would mean the market had unwound the guidance raise itself and reopened the $30–$37 band the stock has not revisited since mid-July. Three non-price developments would do comparable damage to the case: a MolDX or CMS billing article after 2026-08-30 that caps tests per patient per year, narrows the organ set, or adds documentation requirements; FY2026 revenue guidance held flat or trimmed below $490M at the Q3 print; or testing-services growth decelerating toward the ~17% volume growth rate, which would identify the 61% figure as a one-time rate reset. A softer signal that the leg has stopped compounding: the 2026-08-30 date passing with no contractor guidance and no estimate revisions, leaving the name to trade on the Q3 print alone.

Correlation Notes

• MolDX policy is a shared factor, not an idiosyncratic one. The same Medicare contractor framework governs coverage for Natera, Guardant Health, Exact Sciences and Veracyte; a restrictive billing article after 2026-08-30 would be read across the group, and a permissive one likewise.
• Small/mid-cap diagnostics beta. A drawdown in XBI/IBB with multiple compression across the diagnostics complex on no company-specific news would pressure this name regardless of the $490–500M guide.
• The Eurobio divestiture (closed 2026-06-30) removed the European lab-products revenue line, so the remaining business is more concentrated in US reimbursement policy and less exposed to EUR translation than the 2025 comparatives suggest.
• Naveris ties a second leg to oncology MRD adoption, where the reference set is Natera's Signatera and Exact's Oncodetect rather than the transplant peer group.